Solaris Endovascular, Inc. announced that the DEScover clinical trial has completed enrollment. According to the comp ...

A new device for the percutaneous creation of an arteriovenous fistula (AVF) for hemodialysis access in patients with kidney disease has excellent cumulative patency rates out to 2 years and is ...

Please provide your email address to receive an email when new articles are posted on . Due to successful and durable access for hemodialysis through 5 years, percutaneous fistulas can be an ...

Enrollment milestone achieved ahead of schedule as Solaris DE drug-eluting continues to gather additional clinical ...

San Juan Capistrano, Calif. -- A new case report published in the Journal of Vascular Surgery provides one of the first known opportunities to directly visualize the permanent and fused connection ...

SAN JUAN CAPISTRANO, Calif., July 21, 2020 /PRNewswire/ -- A new study shows significant benefits of the Ellipsys ® Vascular Access System in easily and safely creating durable vascular access for end ...

NEW ORLEANS — With the help of nanotechnology, interventionalists might soon be able to create an immediate and permanent percutaneous arteriovenous fistula that has patency and maturation rates ...

SAN JUAN CAPISTRANO, Calif.--(BUSINESS WIRE)--In National Harbor, MD at the Society for Vascular Surgery's 2019 Vascular Annual Meeting, vascular surgeon Alexandros Mallios, M.D. of Institut ...

A new study shows significant benefits of the Ellipsys ® Vascular Access System in easily and safely creating durable vascular access for end-stage renal disease (ESRD) patients who require ...

There is not enough evidence about how well this procedure works. This type of procedure can cause complications. So, it can only be done with special arrangements. This means you will have regular ...

San Juan Capistrano, Calif. - A new study shows significant benefits of the Ellipsys® Vascular Access System in easily and safely creating durable vascular access for end-stage renal disease (ESRD) ...